Clinical Guidelines

Building Better Oral Suspensions for Pediatric & Real-World Use

Greg Thomas, Kiel Laboratories’ Vice President of R&D, discusses oral suspensions, excipients, and patient-centered formulation

  • By

  • February 18, 2026

  • 6 min

Share

Greg Thomas, Vice President of Research & Development at Kiel Laboratories, focuses on enhancing access to therapies for underserved populations and addressing challenges in pediatric medicine formulations. His background in medicinal chemistry and pharmacology shaped his career in drug development, leading projects like Vyscoxa, aimed at creating a much-needed liquid dosage form for juvenile rheumatoid arthritis. Thomas emphasizes the importance of cross-disciplinary collaboration and digital fluency to meet the complexities of modern drug formulations and patient needs.

Original Source(s)

Building Better Oral Suspensions for Pediatric & Real-World Use

Greg Thomas, Kiel Laboratories’ Vice President of R&D, discusses oral suspensions, excipients, and patient-centered formulation

  • February 18, 2026

  • 6 min

Related Content

FDA Broadens Pitolisant Label

The US Food and Drug Administration approves pitolisant (WAKIX) tablets for the treatment of cataplexy in pediatric patients aged 6 years and older with narcolepsy.

Rethinking Acetaminophen in the NICU

Prophylactic treatment closed the ductus arteriosus faster but did not reduce mortality or severe morbidity in extremely premature infants

Omadacycline for Pediatric CAP

Case details intravenous-to-oral strategy after multiple antibiotic hypersensitivity reactions